Julia Velez

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2”.

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2

European Journal of Medicinal Chemistry(2024)10.1016/j.ejmech.2024.116154

N/A

0.546DataRank · unranked

37 citations

Brandon Dale, Kwang‐Su Park, H. Ümit Kanıskan, Xufen Yu, Jian Jin +1 more

Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome

Molecular Therapy(2024)10.1016/j.ymthe.2024.05.034

N/A

0.508DataRank · unranked

14 citations

Yan Xiong, Mi‐Ae Jang, Kwang‐Su Park, Meaghan Donahue, Julia Velez +3 more

Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c01505

N/A

0DataRank · unranked

38 citations

Md Kabir, Youngeun Lee, Ling Xie, Xiaoping Hu, Julia Velez +4 more

Recent advances in developing degraders & inhibitors of lysine methyltransferases

Current Opinion in Chemical Biology(2023)10.1016/j.cbpa.2023.102356

N/A

0DataRank · unranked

10 citations

H. Ümit Kanıskan, Jian Jin, Julia Velez

Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication

medRxiv(2023)10.1101/2023.10.25.23297491

N/A

0DataRank · unranked

6 citations

Ryan N. Sheehy, Yan Xiong, Adil Muneer, John A. Wrobel, Kwang‐Su Park +13 more

Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication

Research Square(2023)10.21203/rs.3.rs-2743792/v1

N/A

0DataRank · unranked

1 citations

Ling Xie, Ryan N. Sheehy, Yan Xiong, Adil Muneer, John A. Wrobel +13 more

Discovery of the First-in-Class G9a/GLP PROTAC Degrader

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.3c02394

N/A

0DataRank · unranked

12 citations

Yulin Han, Hyerin Yim, Peiyi Yang, Zhijie Deng, Kwang‐Su Park +5 more

Discovery of the First-in-class G9a/GLP PROTAC Degrader

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.26.582210

N/A

0DataRank · unranked

2 citations

Yulin Han, Hyerin Yim, Peiyi Yang, Zhijie Deng, Kwang‐Su Park +5 more

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Journal of the American Chemical Society(2021)10.1021/jacs.1c04841

N/A

0DataRank · unranked

144 citations

Fanye Meng, Kwang‐Su Park, Hyerin Yim, Julia Velez, Prashasti Kumar +11 more

Development of a brain-penetrant G9a methylase inhibitor to target Alzheimer’s disease-associated proteopathology

Nature Communications(2025)10.1038/s41467-025-59128-z

N/A

0DataRank · unranked

9 citations

Ryan N. Sheehy, Adil Muneer, Yan Xiong, John A. Wrobel, Feng Zhang +20 more

Discovery of the First-in-Class G9a/GLP Covalent Inhibitors

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c00652

N/A

0DataRank · unranked

46 citations

Yan Xiong, Hyerin Yim, Julia Velez, Nicolas Babault, Prashasti Kumar +3 more